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Epstein-Barr virus (EBV) infection is associated with many lymphoproliferative diseases, such as infectious
mononucleosis and Burkitt’s lymphoma. Consequently, EBV is one of the most extensively studied herpesvi-
ruses. Surprisingly, a putative G protein-coupled receptor (GPCR) gene of EBV, BILF1, has hitherto escaped
attention, yet BILF1-like genes are conserved among all known lymphocryptovirus species, suggesting that they
play a pivotal role in viral infection. To determine the function of EBV BILF1, the activity of this gene and its
products was studied. BILF1-specific mRNA was detected in various EBV-positive cell types and found to be
expressed predominantly during the immediate early and early phases of infection in vitro. Interestingly, in
COS-7 cells transfected with BILF1 expression constructs, a decrease in forskolin-induced CRE-mediated
transcription was measured, as well as an increase in NF-B-mediated transcription. In contrast, CRE-
mediated transcription was increased in EBV-positive Burkitt’s lymphoma cells as well as EBV-positive
lymphoblastoid B cells transfected with BILF1, whereas NF-B-mediated transcription levels remained unaf-
fected in these cells. All observed activities were sensitive to treatment with pertussis toxin, indicating that the
BILF1-encoded protein mediates these activities by coupling to G proteins of the Gi/o class. Finally, reduced
levels of phosphorylated RNA-dependent antiviral protein kinase were observed in COS-7 and Burkitt’s
lymphoma cells transfected with BILF1. Neither of the observed effects required a ligand to interact with the
BILF1 gene product, suggesting that BILF1 encodes a constitutively active GPCR capable of modulating
various intracellular signaling pathways.
G protein-coupled receptors (GPCRs) belong to a super-
family of seven-transmembrane receptors that are capable of
transducing signals from the outside to the cellular interior.
Upon ligand binding, a large number of these receptors can
alter cellular gene expression, thereby causing either differen-
tiation, proliferation, or chemotaxis of the cell. Interestingly,
some herpesviruses as well as poxviruses also encode GPCRs.
Currently, four major viral GPCR gene families have been
identified on the genomes of beta- and gamma-2-herpesvi-
ruses: (i) the human cytomegalovirus (HCMV) UL33 family,
(ii) the HCMV UL78 family, (iii) the HCMV US28 family, and
(iv) the Kaposi’s sarcoma-associated herpesvirus (KSHV)
ORF74 family (47). The four viral GPCR families play distinct
roles in herpesvirus infection. Both the murine cytomegalovi-
rus and rat cytomegalovirus counterparts of UL33, M33, and
R33 are essential for salivary gland tropism (5, 12). The murine
CMV homolog of UL78, M78, was shown to facilitate accu-
mulation of immediate-early viral mRNA (40), and the rat
CMV homolog of UL78, R78, is required for production of
infectious virus in the spleen (25).
It has been postulated that US28 plays a role in chemokine
scavenging (6), migration of infected smooth muscle cells (48),
and cell-to-cell adhesion (21). It was shown that KSHV ORF74
can induce angiogenesis (3) and sarcomagenesis in vivo (20, 23,
38). Several of the viral GPCRs, such as those encoded by
UL33, R33, US28, and KSHV ORF74, were reported to trig-
ger intracellular signaling in a ligand-independent, constitutive
fashion (1, 7, 8, 19, 46, 51), yet the viral GPCRs encoded by
US28 and ORF74 can bind a variety of chemokines through
which intracellular signaling is modulated (1, 14, 28). Since
many mammalian GPCRs are used as targets for drug therapy,
viral GPCRs are generally regarded as interesting targets for
innovative antiviral drugs (47).
All interest in viral GPCRs notwithstanding, one potential
viral GPCR gene, the Epstein-Barr virus (EBV) BILF1 gene
(2), has hitherto escaped attention. Previously, BILF1 was rec-
ognized as a putative GPCR gene on the basis of its homology
with the equine herpesvirus 2 E6 viral GPCR gene (11), yet the
EBV BILF1 gene and its products have not been functionally
examined. EBV, a gamma-1-herpesvirus, can establish life-
long persistence upon infection and transformation of B cells
(44). EBV infection is associated with many lymphoprolifera-
tive diseases, such as infectious mononucleosis, Burkitt’s lym-
phoma, Hodgkin’s disease, and nasopharyngeal carcinoma
(44). Analogous to the crucial functions of other viral GPCRs
in the pathogenesis of infection, BILF1 might play an impor-
tant role in EBV infection and associated diseases.
Here, we set out to determine whether the BILF1 gene
encodes a biologically functional protein. We show that the
* Corresponding author. Mailing address: Department of Medical
Microbiology, University Hospital Maastricht, P.O. Box 5800, 6202
AZ, Maastricht, The Netherlands. Phone: 31 43 3876642. Fax: 31 43
3876643. E-mail: pbe@lmib.azm.nl.
441
EBV BILF1 gene encodes a viral GPCR capable of modulat-
ing CRE-mediated signaling, stimulating NF-B-mediated sig-
naling and inhibiting RNA-dependent protein kinase activa-
tion.
MATERIALS AND METHODS
Cell lines and transfection. COS-7 (ATCC CRL-1651) cells were cultured and
transfected as described previously (7). B95-8 (ATCC CRL 1612), HH514.c16
(22), and JY (42) cells were cultured in RPMI 1640 (Gibco, Paisley, United
Kingdom) supplemented with 10% fetal bovine serum (Biochrom KG, Berlin,
Germany) at 37°C and 5% CO2 in an incubator.
Expression constructs. DNA was extracted from B95-8 cells with an Xtrax
DNA isolation kit (Gull Laboratories, Salt lake City, Utah) and subjected to
PCR. The following primers were used to amplify the predicted BILF1 open
reading frame (ORF): primer 1, AATTGGTACCTCTGACCAGCAAGATGCT
CTCCACCAT; primer 2, AATTGGTACCATGGCCCCCGGGTCCACC; and
primer 3, TATTGGATCCTCAGGTGGACTGGCTAGGCACCC. The se-
quences in italics are derived from GenBank accession number NC_001345.
With primers 1 and 3, a fragment which contained the complete BILF1 ORF was
generated, termed BILF1A. The PCR that included primers 2 and 3 resulted in
a fragment containing a shorter variant of the BILF1 ORF which starts 10 bp
downstream of the first ATG and was termed BILF1B. The PCR products were
digested with Asp718I and BamHI and ligated into Asp718I- and BamHI-di-
gested expression vector pcDEF3 (18), resulting in constructs pBILF1A and
pBILF1B.
Two additional expression constructs were used as positive controls. The first
contains human CMV (HCMV) UL33 and was made as follows. Plasmid p472
(pcDNA3 containing the HCMV UL33 ORF) (8) was digested with HindIII,
treated with Klenow DNA polymerase, and subsequently digested with NotI.
Then, the insert was ligated in EcoRV- and NotI-digested pcDEF3, resulting in
plasmid pUL33. The second control plasmid contains KSHV ORF74, designated
pORF74 (46). The CRE reporter plasmid pTLNC-21CRE was obtained from W.
Born (National Jewish Medical and Research Center, Denver, Colo.) (13). The
NF-B reporter plasmid pNF-B-Luc is from Stratagene (BD Biosciences, Al-
phen aan de Rijn, The Netherlands).
Quantitative RT-PCR. Total RNA isolates from EBV-positive cell lines B95-8,
JY, HH514.c16, C666-1, Namalwa, and X50 as well as from the EBV-negative
cell line Ramos were generously provided by Servi Stevens (Department of
Pathology, Free University of Amsterdam, Amsterdam, The Netherlands). Each
of the RNA samples used for cDNA synthesis was derived from 5  105 cells.
The RNA samples were treated with DNase in a mixture containing 40 mM
Tris-HCl pH 7.4, 6 mM MgCl2, 2 mM dithiothreitol, 7 U of RNA Guard
(Amersham Pharmacia Biotech, Roosendaal, The Netherlands), and 2.5 U of
DNase I (Amersham Pharmacia Biotech) in a final reaction volume of 50 l.
After 1.5 h, the RNA samples were precipitated with isopropanol. The pellets
were washed with 70% ethanol and dissolved in H2O.
Half of each RNA sample was included in a reverse transcription (RT) reac-
tion, which contained 2.5 M random hexanucleotide mixture (Applied Biosys-
tems, Nieuwerkerk aan de IJssel, The Netherlands), first-strand buffer (Invitro-
gen Life Technologies, Breda, The Netherlands), 10 M dithiothreitol, 200 M
deoxynucleoside triphosphates, 7 U of RNA Guard (APB), and 50 U of Super-
Script II (Invitrogen Life Technologies), in a final volume of 20 l. The other half
of each RNA sample was included in reaction mixtures from which reverse
transcriptase was omitted. All mixtures were incubated at 42°C for 1 h, followed
by a reverse transcriptase inactivation step at 70°C for 10 min. Finally, they were
diluted by adding Tris-EDTA to a final volume of 100 l; 5-l samples (corre-
sponding to 2.5  104 cells) were added to PCR mixtures with a total volume of
50 l, containing PCR buffer (Qiagen, Leusden, The Netherlands), 200 M
deoxynucleoside triphosphates, 1.25 U of HotStarTaq (Qiagen),, and 400 nM
primer 4, GGTATGGCGTTGGAGAAGA, and primer 5, TAATCAGCAGGA
GTACCAGACAAA (derived from GenBank accession no. NC_001345).
PCR was performed on a GeneAmp PCR Systems 9600 thermal cycler (Perkin
Elmer, Nieuwerkerk aan de IJssel, The Netherlands) for 4 min at 95°C, followed
by 40 cycles of 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C, and finally 7 min
at 72°C. Samples were analyzed by agarose gel electrophoresis and subsequent
staining with ethidium bromide. For quantitative PCR, 5-l cDNA samples
(corresponding to 2.5  104 cells) were added to 50-l reaction mixtures, each
containing Taqman Universal PCR Master Mix (Applied Biosystems), 900 nM
each of primers 4 and 5, and 125 nM TaqMan probe, 5-carboxyfluorescein-AA
CCTCCCACAGAAATGTGTGCCTGTAC-5-carboxytetramethylrhodamine
(GenBank accession no. NC_001345). The reactions were performed in 96-well
microtiter plates under the following conditions: 2 min at 50°C and 10 min at
95°C, followed by 42 cycles of 95°C for 15 s and 60°C for 1 min. Data were
analyzed with the ABI Prism 7000 sequence detection system software (Applied
Biosystems). For quantification of cDNA molecules, standard curves were gener
ated with dilutions of quantified plasmid pBILF1A.
Reporter gene and inositol phosphate assays. Reporter assays for CRE and
NF-B signaling in COS-7 cells were performed as described previously (19). In
the CRE assay, COS-7 cells were transfected with 5 g of the reporter plasmid
pTLNC-21CRE (containing a luciferase gene controlled by a CRE-specific pro-
moter) (13) and 5 g of either pcDEF3, pBILF1A, or pBILF1. In the NF-B
assay, cells were transfected with 5 g of the reporter plasmid pNF-B-Luc
(containing a luciferase gene controlled by an NF-B-specific promoter) (BD
Biosciences, Alphen aan de Rijn, The Netherlands) and 2 g of either pcDEF3,
pBILF1A, or pBILF1B. Dulbecco’s modified Eagle’s medium without serum and
either with or without pertussis toxin (100 ng/ml) was added to the cells imme-
diately after transfection. COS-7 cells containing pTLNC-21CRE were treated
with 10 M forskolin at 18 h after transfection. At 24 h after transfection, these
cells were lysed and luciferase activities were measured. Luciferase activities in
lysates from COS-7 cells containing pNF-B-Luc were measured at 48 h after
transfection.
The reporter assays were adapted for HH514.c16 and JY cells as follows: 107
cells were suspended in 400 l of 27 mM sodium phosphate (pH 7.5) and 150
mM sucrose and mixed with 5 g of reporter plasmid pTLNC-21CRE or pNF-
B-Luc and 2 to 5 g of either pcDEF3, pBILF1A, or pBILF1B. The suspensions
were transferred to 0.4-cm electroporation cuvettes (Bio-Rad Laboratories,
Veenendaal, The Netherlands), incubated on ice for 10 min, and electroporated
with a Gene Pulser II apparatus equipped with a radio frequency (RF) module
(Bio-Rad Laboratories). The RF module was set to 340 V, 40 kHz, 100%
modulation, 4 ms per burst, five bursts, and a 1-s burst interval. After electro-
poration, the cuvettes were incubated on ice for 10 min, and the contents were
transferred to 12-well plates containing RPMI medium without serum with or
without 100 ng of pertussis toxin per ml and kept at 37°C in a 5% CO2 incubator.
At 24 to 48 h after transfection, suspensions were pelleted and lysed, and
luciferase activities were measured. Myo-[3H]inositol phosphate accumulation in
transfected COS-7 cells was determined as described previously (7). In each of
the experiments, samples were analyzed in triplicate. Experiments were per-
formed at least three times.
SDS-PAGE and Western blotting. Pellets of COS-7 and HH514.c16 cells, each
consisting of 107 cells, were lysed in a solution containing 20 mM morpholinepro-
panesulfonic acid (MOPS, pH 7.0), 2 mM EGTA, 5 mM EDTA, 30 mM sodium
fluoride, 40 mM -glycerophosphate, 10 mM sodium pyrophosphate, 2 mM
sodium orthovanadate, and 0.5% (wt/vol) Nonidet P-40 at 0°C. The lysed sam-
ples were centrifuged for 1 h at 24,000  g. Supernatant fractions containing 100
g of protein were mixed with sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis (PAGE) sample buffer, boiled for 5 min, and separated by SDS–
12% PAGE, according to the Laemmli method (31). The separated proteins
were transferred to a Hybond C-Super membrane (Amersham Pharmacia Bio-
tech) and incubated with either anti-RNA-dependent protein kinase (PKR)
(Upstate Biotechnology/Brunswig Chemie, Amsterdam, The Netherlands) or
anti-phospho-T451-PKR (BioSource International, Nivelles, Belgium) polyclonal
antibodies, followed by incubation with peroxidase-conjugated goat anti-rabbit
monoclonal antibodies (Dako, Glostrup, Denmark).
The protein bands were detected with the ECL luminescence detection system
(Amersham Pharmacia Biotech) and recorded with the FluorChem image anal-
ysis system (Alpha Innotech Corporation, San Leandro, Calif.). Band intensities
were quantified with image analysis program ImageJ (version 1.31; Research
Services Branch, National Institute of Mental Health, Bethesda, Md. [http:
//rsb.info.nih.gov/ij]). All experiments were performed at least three times.
RESULTS
EBV BILF1 is member of a distinct GPCR-like gene family.
Both the sequences and genomic positions of BILF1-like genes
are conserved among all of the currently known gamma-1-
herpesviruses. In addition, BILF1 homologs are found in a
subset of gamma-2-herpesvirus species. As shown in Fig. 1,
each member of the BILF1 family is positioned at the 5 end of
a conserved gene block that includes the viral DNA polymer-
ase gene. The ORF74-like genes, however, are positioned near
another conserved gene block that includes the large tegument
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protein gene. This indicates that BILF1 represents an inde-
pendent, as yet uncharacterized, family of herpesvirus GPCR
genes.
BILF1 is transcribed in various EBV-positive cell lines. To
examine the kinetics of BILF1 expression during EBV infec-
tion, RNA samples derived from several EBV-positive cell
types were subjected to RT-PCR analysis. First, RNA samples
were prepared from the Burkitt’s lymphoma cell line
HH514.c16, in which EBV gene expression is highly restricted
to latency type I (22, 35). The samples were taken from un-
treated cells as well as from cells in which EBV replication was
stimulated by phorbol ester and butyrate treatment (49). In
addition, these treatments were also carried out in the pres-
ence of phosphonoacetic acid in order to block viral DNA
replication and EBV late-phase protein expression. The RNA
samples were subjected to BILF1-specific RT-PCR in either
the presence or absence of reverse transcriptase. BILF1-spe-
cific fragments were detected in all reverse transcriptase-
treated samples but not in untreated samples (Fig. 2A), indi-
cating that BILF1-specific cDNA rather than viral genomic
DNA was detected.
BILF1 mRNA levels were quantified by real-time PCR. Ap-
proximately 104 BILF1-specific RNA copies per 106
HH514.c16 cells were measured in samples derived from un-
stimulated cells (Fig. 2B). At 1, 2, 4, and 5 days after EBV
stimulation, RNA levels were approximately 100 times higher
than before stimulation (Fig. 2B). These levels were similar in
both phosphonoacetic acid-treated and untreated cells. The
results indicate that BILF1 transcription is correlated with
activation of EBV replication, yet transcription occurs inde-
pendently of viral DNA replication, suggesting that BILF1 is
either an immediate-early or early gene.
To measure BILF1 transcription levels in other cell types,
RNA samples from the following lines were included in a
subsequent RT-PCR assay: B95-8 (an EBV-positive marmoset
lymphoblastoid cell line) (36), JY (lymphoblastoid cell line
derived from human lymphocytes infected with B95-8-derived
EBV) (42), X50-7 (lymphoblastoid cell line derived from hu-
man umbilical cord lymphocytes infected with EBV B98-8)
(37), C666-1 (a nasopharyngeal carcinoma cell line) (24), Na-
malwa (an EBV-positive Burkitt’s lymphoma cell line) (32),
and Ramos (an EBV-negative Burkitt’s lymphoma cell line)
(29). PCR fragments were generated with all reverse tran-
scriptase-treated samples with the exception of those derived
from Ramos cells (Fig. 2C).
In order to quantify BILF1 mRNA levels, the cDNA sam-
ples from each of the cell lines were analyzed by real-time
PCR. As shown in Fig. 2D, BILF1 mRNA levels ranged be-
tween approximately 103 and 105 copies per 106 cells. This
indicated that the level of BILF1 transcription in various of
EBV-positive cell lines is 10 to 100 times lower than that in
stimulated HH514.c16 cells (Fig. 2B). The low level of BILF1
mRNA expression in Namalwa cells is comparable to the level
observed in uninduced HH514.c16 cells and correlates with the
restricted EBV latency I type in both cell lines. The interme-
diate levels of BILF1 expression in noninduced B-cell lines
B95-8, JY, and X50/7 and the nasopharyngeal carcinoma line
C666-1 may be related to the spontaneous lytic cycle induction
in 1 to 5% of the cells of each of these lines (24, 41). We
conclude that BILF1 is transcribed (i) at low levels in unstimu-
lated EBV-positive B-cell lines under tight latency, (ii) at in-
termediate levels in lymphoblastoid cell line and the nasopha-
ryngeal carcinoma-derived C666-1 line, and (iii) at high levels
upon full induction of the lytic cycle.
EBV GPCR signals through Gi/o but not through Gq/11. To
determine whether EBV BILF1 encodes a functional GPCR,
we set out to generate BILF1 expression constructs. Previ-
ously, the ATG initiation codon of the BILF-1 open reading
frame was predicted to be localized to positions 151703 to
151701 of the EBV sequence (GenBank accession no.
NC_001345). However, 10 bp downstream of this codon, a
second ATG is present. In contrast to the “first” ATG, the
second conforms to the Kozak consensus for eukaryotic trans-
lation initiation sites (30), which would favor the second ATG
as the authentic initiation codon. However, we found the first
eight amino acid residues of BILF1 to be identical to those of
its homolog from cercopithecine herpesvirus 15, with the ex-
ception of the second methionine, which is a leucine in the
cercopithecine herpesvirus BILF1-like sequence. This obser-
vation would predict the first ATG as the authentic initiation
codon. Based on these considerations, two different expression
plasmids were made, one containing the BILF1 ORF begin-
ning at the first putative start codon (plasmid pBILF1A) and
FIG. 1. EBV BILF1 and KSHV ORF74 belong to different viral
GPCR gene families. The lines represent herpesvirus genomes. The
symbols indicate gene positions, which were derived from GenBank
accession nos. AY037858, NC_001345, NC_001650, NC_001826,
NC_002531, NC_003409, and NC_004367. Open symbols represent
viral GPCR genes. The names of viral GPCR genes are indicated
above their corresponding symbols. Genomes and gene positions are
drawn to scale. EBV, Epstein-Barr virus; CeHV15, cercopithecine
herpesvirus 15; CaHV-3, callitrichine herpesvirus 3; AlHV-1, alcepha-
line herpesvirus 1; EHV2, equine herpesvirus 2; KSHV, Kaposi’s sar-
coma-associated herpesvirus; MHV-68, murine gammaherpesvirus 68;
, BILF1 family; ƒ, ORF74 family; ƒ, equine herpesvirus 2 E1; ,
large tegument protein family; Œ, DNA polymerase family.
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the other containing the BILF1 ORF beginning at the second
putative start codon (plasmid pBILF1B).
To assess whether the EBV GPCR possesses signaling ac-
tivity, two types of assays were performed, each of which in-
volved a reporter gene, luciferase, under the control of a pro-
moter containing either CRE-specific or NF-B-specific
elements. In the first reporter gene experiment with COS-7
cells, a CRE reporter plasmid was cotransfected with either
plasmid pBILF1A, pBILF1B, pcDEF3 as a negative control, or
pORF74 as a positive control. As a result, a slight decrease in
CRE-driven gene activation was observed in cells transfected
with pBILF1A, pBILF1B, or pORF74 (data not shown). Since
CRE-driven gene activation induced by forskolin can be inhib-
ited through Gi/o-mediated signaling, cells were incubated with
forskolin in either the presence or absence of the Gi/o inhibitor
pertussis toxin. Interestingly, the luciferase activities in cells
transfected with either pBILF1A, pBILF1B or pORF74 were
significantly lower (65 to 86%) than those in cells transfected
with pcDEF3 (Fig. 3A), indicating that expression of BILF1
inhibits forskolin-induced CRE-driven gene activation. More-
over, pertussis toxin treatment of cells transfected with
pBILF1A or pBILF1B reversed the inhibition of CRE-driven
gene activation (Fig. 3A), indicating that BILF1 expression
inhibits CRE-driven gene activation through Gi/o coupling.
When increasing concentrations of either pBILF1A or
pBILF1B were used for transfection, decreasing levels of lu-
ciferase activity were found (Fig. 3B). Thus, BILF1/Gi/o-medi-
ated signaling is BILF1 expression level dependent. Taken
together, these results show that the EBV BILF1 gene encodes
a functional Gi/o-coupling GPCR. Since the signaling assays
were performed in serum-free medium, it is likely that the
EBV GPCR signals in a ligand-independent, constitutive fash-
ion.
To study EBV GPCR signaling in cells types relevant to
EBV infection, the CRE reporter gene assay was performed
with the EBV-positive Burkitt’s lymphoma line HH514.c16.
Surprisingly, luciferase activities in HH514.c16 cells trans-
fected with either pBILF1A or pBILF1B were 170 to 200% of
that in cells transfected with the negative control DNA pc-
DEF3 (Fig. 3C). Upon pertussis toxin treatment (Fig. 3C), this
activity was reduced to negative-control levels, indicating that
viral GPCR signals in a Gi/o-dependent manner. Similar results
were obtained by repeating this experiment with an EBV-
positive lymphoblastoid B-cell line, JY. CRE activity in JY
cells transfected with either BILF1A or BILF1B was increased
to 280 to 300% of that in cells transfected with the negative
control DNA pcDEF3 (Fig. 3D). Similar to HH514.c16 cells,
this activity could be reduced to negative-control levels by
pertussis toxin treatment (Fig. 3D).
To determine whether the difference in BILF1-mediated
responses between COS-7 and B cells was specific for BILF1 or
represented a more general phenomenon, the CRE assay was
repeated with the KSHV ORF74 gene. Similar to BILF1A and
FIG. 2. EBV BILF1 is an early-phase gene that is transcribed in
various EBV-positive cell types. (A) The BILF1-specific RT-PCR as-
say detects cDNA but not genomic EBV DNA in HHV514.c16 cells.
Each panel represents an ethidium bromide-stained agarose gel con-
taining RT-PCR fragments. (B) BILF1 transcription is upregulated in
HH514.16c cells stimulated with phorbol ester and butyric acid and
either with or without phosphonoacetic acid treatment. The graph
indicates BILF1-specific RNA levels measured by TaqMan reactions.
(C) The BILF1-specific RT-PCR assay detects cDNA but not genomic
EBV DNA in various EBV-positive cell types. (D) BILF1-specific
RNA levels in various EBV-positive cell lines. The effectiveness of the
phosphonoacetic acid treatment was confirmed by immunoblot, in
which the late-phase EBV viral capsid antigen could not be detected
(data not shown). RT, reverse transcriptase; PAA, phosphonoacetic
acid; C666-1, a nasopharyngeal carcinoma cell line; B95-8, an EBV-
positive marmoset lymphoblastoid cell line; JY, an EBV-positive hu-
man lymphoblastoid cell line; Namalwa, an EBV-positive Burkitt’s
lymphoma cell line; X50, a cord blood-derived EBV-positive lympho-
blastoid cell line; Ramos, an EBV-negative Burkitt’s lymphoma cell
line.
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BILF1B, ORF74 expression significantly reduces CRE-medi-
ated gene activation in COS-7 cells (Fig. 3A), whereas
pORF74 expression increases CRE-mediated gene activation
in HH514.c16 cells (data not shown) and JY cells (Fig. 3E). We
therefore hypothesize that the differential CRE response in
COS-7 and B cells is cell type rather than receptor dependent.
In a second reporter gene experiment, an NF-B reporter
plasmid was cotransfected with either pcDEF3, pBILF1A, or
pBILF1B in COS-7 cells. NF-B-mediated transcription in
cells transfected with either pBILF1A or pBILF1B was signif-
icantly higher (up to 300% of the negative-control levels) than
in cells transfected with pcDEF3 (Fig. 4A). In contrast, lucif-
erase activities in lysates from pertussis toxin-treated cells
transfected with pBILF1A or pBILF1B did not differ signifi-
cantly from those derived from cells transfected with pcDEF3
(Fig. 4A). This shows that, like the CRE-driven transcription,
the NF-B-driven gene activation by BILF1 in COS-7 cells is
also mediated by coupling to Gi/o proteins. As shown in Fig.
4B, transfection of increasing concentrations of either
pBILF1A or pBILF1B resulted in increasing levels of lucif-
erase activity. This indicates that BILF1-mediated NF-B ac-
tivation is expression level dependent.
To determine whether the EBV GPCR also signals to
NF-B in physiologically relevant cell types, the NF-B re-
porter gene assay was repeated with cell lines HH514.c16 and
JY. However, in contrast to the activity of viral GPCR in
COS-7 cells, the receptor did not induce detectable levels of
NF-B-driven transcription in either HH514.c16 or JY cells
(Fig. 4C and D). The differences in BILF1-mediated signaling
between COS-7 cells and both HH514.c16 and JY cells are
most likely due to differential expression of downstream sig-
naling partners within these cell lines, such as increased levels
of endogenous NF-B in EBV-infected cells (27).
In addition to the assessment of EBV GPCR coupling to
Gi/0 by conducting reporter gene assays, the possibility of EBV
GPCR coupling to another G protein class was examined.
COS-7 cells endogenously express two members of the Gq
class, Gq and G11 (53). Upon activation, Gq/11 proteins trigger
phospholipase C-mediated signaling, which was assessed by
measuring the accumulation of inositol phosphate. Cells trans-
fected with either pcDEF3, pBILF1A, pBILF1B, pUL33, or
pORF74 were incubated with 3H-labeled inositol, after which
accumulation of radiolabeled inositol phosphate was mea-
sured. Cells transfected with either pUL33 or pORF74 con-
tained significantly higher levels of radiolabeled inositol phos-
phate than cells transfected with pcDEF3 (Fig. 5). By contrast,
radiolabeled inositol phosphate levels in cells transfected with
either pBILF1A or pBILF1B were similar to those in pcDEF3-
transfected cells (Fig. 5), indicating that the BILF1 gene prod-
uct does not constitutively signal through the phospholipase
C pathway via Gq/11.
EBV GPCR induces inhibition of PKR phosphorylation. To
examine the influence of the EBV GPCR on the phosphory-
lation status of cellular protein kinases, extracts of viral GPCR-
expressing COS-7 cells were used in an immunoblot screen
with an array of antibodies directed against a variety of phos-
phoproteins (Kinetworks Phospho-site screen 1.3; Kinexus,
Vancouver, Canada). Interestingly, this screen revealed a sig-
nificant change in the level of phosphorylated RNA-dependent
protein kinase (PKR) upon BILF1 expression (data not
FIG. 3. BILF1 drives CRE-mediated gene expression. CRE-driven luciferase expression in COS-7 cells transiently cotransfected with reporter
plasmid pTLNC-21CRE and 5 g (A) or increasing amounts (B) of either pcDEF3, pcDEF3/BILF1A, or pcDEF3/BILF1B. Cells were stimulated
with forskolin (10 M) for 6 h before luciferase activities were measured. When amounts of either pcDEF3/BILF1A or pcDEF3/BILF1B lower
than 5 g were used, pcDEF3 was added to a total of 5 g of plasmid DNA per transfection. CRE-driven luciferase expression in HH514.c16
(C) and JY (D) cells transiently transfected with reporter plasmid pTLNC-21CRE and either pcDEF3, pcDEF3/BILF1A, or pcDEF3/BILF1B.
(E) CRE-driven luciferase expression in JY cells transiently transfected with pTLNC-21CRE and either pcDEF3 or pORF74. RLU, relative light
units, expressed as a percentage of the value obtained with pcDEF3.
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shown). PKR is an interferon-inducible enzyme that plays an
important role in intracellular antiviral defense (26). Phos-
phorylation of PKR can result in shutdown of cellular protein
synthesis and apoptosis (52). The viral GPCR-induced change
in the phosphorylation status of PKR was investigated further
by subjecting extracts of COS-7 cells transfected with either
pcDEF3, pBILF1A, or pBILF1B to immunoblot analysis with
antibodies specific for either PKR or phospho-PKR. The anti-
PKR antibodies were used to normalize the total cellular PKR
levels between the different samples and as a reference for
phospho-PKR levels. The anti-phospho-PKR antibodies were
used to measure PKR phosphorylation levels at residue T451, a
residue essential for PKR activation (34).
As shown in Fig. 6A, the levels of PKR did not differ signif-
icantly between pcDEF3-, pBILF1A-, and pBILF1B-trans-
fected cells (lanes 1, 2, and 3, respectively). By contrast, the
levels of phosphorylated PKR in cells transfected with either
pBILF1A or pBILF1B (Fig. 6A, lanes 5 and 6, respectively) are
significantly lower, 20% and 40%, respectively, relative to the
negative control level in pcDEF3-transfected cells (Fig. 6A,
lane 4). Similar effects were observed in HH514.c16 cells.
Whereas total cellular PKR levels were similar in all samples
(Fig. 6B, lanes 1 to 6), the levels of phospho-PKR in cells
transfected with either pBILF1A or pBILF1B (Fig. 6B, lanes 9
and 11) were 39% and 21%, respectively, relative to the basal
level in pcDEF3-transfected cells (Fig. 6B, lane 7). Interest-
ingly, phospho-PKR levels were also lower, 24% and 16% in
pBILF1A- and pBILF1B-transfected HH514.c16 cells treated
with pertussis toxin, respectively (Fig. 6B, lanes 10 and 12).
Thus, the BILF1-mediated decrease in PKR phosphorylation
at residue T451 is independent of Gi/o coupling.
In summary, while total PKR levels remain constant, the
phosphorylation of PKR at T451 is downregulated upon EBV
GPCR expression. By virtue of this activity, the EBV GPCR
inhibits a crucial cellular antiviral response pathway. Although
inhibition of this pathway has previously been described for
several other viral proteins, EBV GPCR represents the first
example of a GPCR that inhibits PKR phosphorylation.
DISCUSSION
This is the first report of a functional GPCR encoded by a
gamma-1-herpesvirus gene, EBV BILF1. Until now, genes
coding for such viral GPCRs had been identified exclusively on
the genomes of poxviruses and beta- and gamma-2-herpesvi-
ruses (reviewed in references 39 and 47). The BILF1 gene was
identified following the sequencing of the complete EBV ge-
nome (2). The gene was subsequently predicted to encode a
seven-transmembrane protein (4) and reported to show se-
quence similarity with the putative equine herpesvirus 2 viral
GPCR gene E6 (11). In this study, we have demonstrated that
BILF1 encodes a functional GPCR which is able to couple to
proteins of the Gi/o class. This coupling results in differential
effects on CRE-mediated gene expression in different cell
lines: a decrease in CRE-driven expression is seen in COS-7
cells, whereas an increase is seen in HH514.c16 and JY cells.
This difference is not unique for the BILF1-encoded viral
GPCR, as KSHV ORF74 differentially modulates CRE-medi-
ated gene expression in these cell types in a similar fashion. We
hypothesize that these differential effects are caused by the
expression and, thus, activation of different subsets of G pro-
teins in COS-7 cells on the one hand and B-cell lines on the
other.
Another consequence of the activation of Gi/o proteins by
the BILF1-encoded GPCR in COS-7 cells is upregulation of
NF-B-mediated gene expression. In addition, we found that
BILF1 expression resulted in inhibition of RNA-dependent
protein kinase activation, independent of coupling to Gi/o pro-
teins. This suggests the coupling of the BILF1 gene product to
FIG. 4. BILF1 drives NF-B-mediated gene expression. NF-B-driven luciferase expression in COS-7 cells transiently transfected with reporter
plasmid pNF-B-Luc and 2 g (A) or increasing amounts (B) of either pcDEF3, pcDEF3/BILF1A, or pcDEF3/BILF1B. When amounts of either
pcDEF3/BILF1A or pcDEF3/BILF1B lower than 8 g were used, pcDEF3 was added to a total of 8 g of plasmid DNA per transfection.
NF-B-driven luciferase expression in HH514.c16 (C) and JY (D) cells transiently transfected with reporter plasmid pNF-B-Luc and either
pcDEF3, pcDEF3/BILF1A, or pcDEF3/BILF1B. RLU, relative light units, expressed as a percentage of the value obtained with pcDEF3. Solid
bars, untreated; open bars, pertussis toxin treated (100 ng/ml).
FIG. 5. Viral GPCR-mediated induction of inositol phosphate
(InsP) accumulation. COS-7 cells were transiently transfected with
either pcDEF3, pcDEF3/BILF1A, pcDEF3/BILF1B, pcDEF3/UL33,
or pcDEF3/ORF74. At 48 h after transfection, inositol phosphate
accumulation was measured and is expressed as a percentage of that in
pcDEF3.
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other G protein signaling pathways. Moreover, each of these
responses occurred in the absence of any exogenously added
ligands, suggesting that EBV GPCR possesses ligand-indepen-
dent, constitutive signaling activity. Previously, members of
three other viral GPCR families were found to display consti-
tutive activity through coupling to different G proteins. The
HCMV UL33-encoded viral GPCR is active through Gs, Gi/o,
and Gq coupling (8). The HCMV US28-encoded GCPR is
constitutively active through association with Gq/11 (7). The
viral GPCR encoded by KSHV ORF74 is constitutively active
through Gi/o (10, 46) and Gq/11 coupling (1) and G13 (45). In
contrast to the KSHV GPCR, we found that EBV GPCR was
unable to mediate constitutive inositol phosphate-related sig-
naling through Gq/11 coupling. This shows that these receptors
have fundamentally different properties. Whether the EBV
GPCR is able to interact constitutively with alternative G pro-
tein classes, such as G12/13, remains to be investigated.
Of all GPCRs other than those encoded by members of the
BILF1 gene family, human CXCR3A and KSHV GPCR show
the highest homology with EBV GPCR (20.8% and 21.2%,
respectively). The human chemokine receptor CXCR3A can
interact with the CXC chemokines CXCL9/MIG, CXCL10/IP-
10, and CXCL11/IP-9 (9, 33). The KSHV-encoded viral GPCR
can interact with CXC chemokines CXCL1/GRO, CXCL8/
IL-8, and CXCL10/IP-10 as well as KSHV vMIP-II (1, 15, 16,
17). Several experiments were performed to determine
whether EBV GPCR interacts with these chemokines as well
as with chemokines of the CC and CX3C families. However, in
an assay with radiolabeled CXCL1/GRO, CXCL8/IL-8,
CXCL10/IP-10, CCL4/MIP-1, CCL5/RANTES, and
CX3CL1/fractalkine, none of these chemokines were able to
bind specifically to BILF1-expressing cells (data not shown).
Additionally, several chemokine species, CCL2/MCP-1, CCL3/
MIP-1, CCL4/MIP-1, CCL5/RANTES, CCL11/eotaxin,
CCL19/MIP-3, CXCL1/GRO, CXCL4/PF-4, CXCL8/IL-8,
CXCL9/MIG, CXCL10/IP-10, CXCL11/IP-9, CXCL12a/SDF-
1, CX3CL1/fractalkine, and KSHV vMIP-II, were assayed for
their ability to alter intracellular signaling in BILF1-trans-
fected cells, but none of these chemokines was found to have
a significant effect on InsP accumulation or either cyclic AMP-
or NF-B-mediated signaling (data not shown). Consequently,
the EBV GPCR remains an orphan receptor. Nevertheless, the
search for chemokines and other ligands which could poten-
tially bind to this receptor is still in progress.
Expression of EBV GPCR results in reduction of cellular
PKR phosphorylation. PKR is a double-stranded RNA-depen-
dent protein kinase that functions in cellular antiviral defense
by shutting down the host protein synthesis system and induc-
ing apoptosis (26). Our data suggest that the EBV GPCR can
interfere with this cellular antiviral defense system. Moreover,
EBV GPCR is the first GPCR reported to be capable of
altering PKR phosphorylation levels. Previously, we deter-
mined that the rat cytomegalovirus R33 gene, which encodes a
constitutively active GPCR, did not affect PKR phosphoryla-
tion in transfected COS-7 cells (data not shown). This indicates
that PKR inhibition is not a general phenomenon induced
upon viral GPCR expression. Until now, alteration of PKR
phosphorylation was only reported for cellular non-GPCR-
related signal transduction pathways, such as those triggered
by viral double-stranded RNA, lipopolysaccharide, interleu-
kin-1, tumor necrosis factor alpha, heat shock, platelet-derived
growth factor, or interleukin-3 deprivation (reviewed in refer-
ence 52). Some EBV-specific factors, such as the RNA mole-
cules EBER1 and EBER3 (50), as well as the lytic-phase post-
translational regulator protein SM (43) were also shown to
reduce PKR phosphorylation. Thus, the discovery of EBV
GPCR-dependent PKR inhibition sheds new light on the PKR-
mediated cellular response to biological stress. Future studies
will focus on elucidation of the signaling pathways through
which BILF1 mediates inhibition of PKR phosphorylation.
It was previously reported that BILF1-derived transcripts
are expressed in lymphoblastoid cell line derived from blood
leukocytes infected with EBV, B95-8 cells, as well as in EBV-
positive Burkitt’s lymphoma P3HR-1 cells (4). We examined
an extended range of EBV-positive blood leukocyte cell lines
as well as nasopharyngeal carcinoma cells, each of which was
found to contain significant levels of BILF1-specific RNA.
FIG. 6. BILF1 expression inhibits PKR phosphorylation. Cytoplas-
mic lysates of cells transfected with either pcDEF3, pcDEF3/BILF1A,
or pcDEF3/BILF1B were separated by SDS–12% PAGE and trans-
ferred to a carrier membrane. The blots were stained with monoclonal
antibodies specific for either PKR or phospho-T451-PKR and visual-
ized by chemiluminescence. (A) Chemiluminogram of a Western blot
containing COS-7 cell lysates and (B) HH514.c16 cell lysates. PTx,
pertussis toxin.
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Additionally, we showed that BILF1 transcription is dramati-
cally upregulated upon phorbol ester treatment of latently
infected cells, which induces EBV reactivation (49). This no-
tion suggests that the EBV GPCR plays a role during produc-
tive infection rather than during latency.
In previous studies, the KSHV ORF74 gene has been im-
plicated in the pathogenesis of Kaposi’s sarcoma (3, 20, 23, 38).
Similarly, the EBV GPCR may play a crucial role in the patho-
genesis of EBV-induced diseases. It is therefore imperative to
investigate the relationship between EBV GPCR-mediated
signaling, as described in this report, and EBV infection in a
wider perspective. As the BILF1-like genes are conserved
among the genomes of all known gamma-1-herpesviruses, we
expect this relation to be substantial.
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